A phase 1 study of triple-targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF-mutated cancers

By sjmartinez • April 30, 2024

Algazi AP, Moon J, Lao CD, Chmielowski B, Kendra KL, Lewis KD, Gonzalez R, Kim K, Godwin JE, Curti BD, Latkovic-Taber M, Lomeli SH, Gufford BT, Scumpia PO, Lo RS, Othus M, Ribas A. A phase 1 study of triple-targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF-mutated cancers. Cancer. 2024 May 15;130(10):1784-1796. doi: 10.1002/cncr.35200. Epub 2024 Jan 23. PMID: 38261444.

Tags: Dermatology, Hematology/Oncology, melanoma, mitogen‐activated protein kinase, nonsmall cell lung cancer, papillary thyroid carcinoma, phosphatidylinositol‐3' kinases, proto‐oncogene proteins B‐RAF, Publications

Dynamics of Th1/Th17 responses and antimicrobial pathways in leprosy skin lesions

Andrade PR, Ma F, Lu J, de Anda J, Lee EY, Agak GW, Dobry CJ, de Andrade Silva BJ, Teles RM, Mansky LA, Perrie J,[...]

Mammary tissue microbiome analysis in PyMT mice reveals Methylobacteria as a commensal organism with potential therapeutic applications

Chan AA, Caron C, Navarrete M, Lee CK, Noguti J, Bui JD, Lee DJ. Mammary tissue microbiome analysis in PyMT mice reveals Methylobacteria as a[...]

Psoriasis

Armstrong AW, Blauvelt A, Callis Duffin K, Huang YH, Savage LJ, Guo L, Merola JF. Psoriasis. Nat Rev Dis Primers. 2025 Jun 26;11(1):45. doi: 10.1038/s41572-025-00630-5.[...]